Cue Biopharma, Inc.
Close on Oct 19, 2026
- Market cap
- $101.96M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | $7.90M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | After market close | $21.90M | $0.01 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $2.10M | $-0.07 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $3.00M | $-0.09 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $400.00K | $-0.17 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | $1.60M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $3.30M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | $1.70M | $-0.25 | – |
| Q1 FY2020 Ended Mar 31, 2020 | May 19, 2020 | After market close | – | – | – |
| Q4 FY2019 Ended Dec 31, 2019 | Mar 17, 2020 | After market close | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Nov 12, 2019 | After market close | – | – | – |
Press releases
Announcements Cue Biopharma filed with the SEC
Cue Biopharma Announces Positive Topline Results from CUE-221
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
2026 ©© 20 20 26 26 C C ue ue B B ioip oh pa hr a ma rma ©2024 Cue Biopharma CONFIDENTIAL DO NOT DISTRIBUTE
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma Announces $50.0 Million Private Placement
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Cue Biopharma Announces $30 Million Private Placement
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.2 to Form 8-K
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma Announces Pricing of $10 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
Executive or director change · Other events · EX-99.1 to Form 8-K
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K